DK3515492T3 - Midler mod cancer og fremstilling heraf - Google Patents
Midler mod cancer og fremstilling heraf Download PDFInfo
- Publication number
- DK3515492T3 DK3515492T3 DK17853991.2T DK17853991T DK3515492T3 DK 3515492 T3 DK3515492 T3 DK 3515492T3 DK 17853991 T DK17853991 T DK 17853991T DK 3515492 T3 DK3515492 T3 DK 3515492T3
- Authority
- DK
- Denmark
- Prior art keywords
- manufacture
- against cancer
- agents against
- agents
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398783P | 2016-09-23 | 2016-09-23 | |
| PCT/US2017/052967 WO2018057897A1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3515492T3 true DK3515492T3 (da) | 2023-08-28 |
Family
ID=61690726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17853991.2T DK3515492T3 (da) | 2016-09-23 | 2017-09-22 | Midler mod cancer og fremstilling heraf |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858371B2 (da) |
| EP (1) | EP3515492B1 (da) |
| JP (1) | JP7111722B2 (da) |
| KR (1) | KR102646702B1 (da) |
| CN (1) | CN109862916A (da) |
| AU (1) | AU2017331260A1 (da) |
| BR (1) | BR112019005885A2 (da) |
| CA (1) | CA3037883A1 (da) |
| DK (1) | DK3515492T3 (da) |
| IL (1) | IL265521B1 (da) |
| MA (1) | MA46291A (da) |
| MX (1) | MX2019003368A (da) |
| RU (1) | RU2019111768A (da) |
| WO (1) | WO2018057897A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017331260A1 (en) | 2016-09-23 | 2019-05-16 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| WO2009031999A1 (en) * | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 and analogs with antitumor activity and method for their preparation |
| CN101417934B (zh) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | 分离自牛樟芝萃取物的化合物 |
| ES2545977T3 (es) | 2008-03-18 | 2015-09-17 | Genentech, Inc. | Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso |
| US8969405B2 (en) * | 2008-06-21 | 2015-03-03 | St. Jude Children's Research Hospital | Anticancer compounds and methods of making and using same |
| US20150025017A1 (en) * | 2012-02-28 | 2015-01-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating cancer |
| AU2013340449B2 (en) * | 2012-11-05 | 2017-11-30 | Pfizer Inc. | Spliceostatin analogs |
| WO2014100367A1 (en) * | 2012-12-21 | 2014-06-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| US20140274979A1 (en) * | 2013-03-13 | 2014-09-18 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
| AU2014292132B2 (en) | 2013-07-15 | 2018-11-08 | Marcus Conrad | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death |
| KR102092569B1 (ko) * | 2013-09-17 | 2020-03-25 | 엘지디스플레이 주식회사 | 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법 |
| CA2931111C (en) * | 2013-11-19 | 2022-03-15 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| MA45258A (fr) * | 2016-06-08 | 2019-04-17 | Univ Rice William M | Dérivés de la thailanstatine a, méthodes de traitement et méthodes de synthèse de ceux-ci |
| AU2017331260A1 (en) | 2016-09-23 | 2019-05-16 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2017
- 2017-09-22 AU AU2017331260A patent/AU2017331260A1/en active Pending
- 2017-09-22 MA MA046291A patent/MA46291A/fr unknown
- 2017-09-22 KR KR1020197011144A patent/KR102646702B1/ko active IP Right Grant
- 2017-09-22 WO PCT/US2017/052967 patent/WO2018057897A1/en unknown
- 2017-09-22 BR BR112019005885-0A patent/BR112019005885A2/pt unknown
- 2017-09-22 JP JP2019537750A patent/JP7111722B2/ja active Active
- 2017-09-22 EP EP17853991.2A patent/EP3515492B1/en active Active
- 2017-09-22 MX MX2019003368A patent/MX2019003368A/es unknown
- 2017-09-22 CA CA3037883A patent/CA3037883A1/en active Pending
- 2017-09-22 DK DK17853991.2T patent/DK3515492T3/da active
- 2017-09-22 IL IL265521A patent/IL265521B1/en unknown
- 2017-09-22 US US16/335,378 patent/US10858371B2/en active Active
- 2017-09-22 RU RU2019111768A patent/RU2019111768A/ru unknown
- 2017-09-22 CN CN201780065546.7A patent/CN109862916A/zh active Pending
-
2020
- 2020-11-09 US US17/092,829 patent/US11851441B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10858371B2 (en) | 2020-12-08 |
| US20190218228A1 (en) | 2019-07-18 |
| EP3515492A1 (en) | 2019-07-31 |
| EP3515492A4 (en) | 2020-04-08 |
| MX2019003368A (es) | 2019-09-16 |
| EP3515492B1 (en) | 2023-07-26 |
| KR102646702B1 (ko) | 2024-03-11 |
| US20210395265A1 (en) | 2021-12-23 |
| WO2018057897A1 (en) | 2018-03-29 |
| BR112019005885A2 (pt) | 2020-06-02 |
| JP2019529563A (ja) | 2019-10-17 |
| RU2019111768A3 (da) | 2020-11-24 |
| CN109862916A (zh) | 2019-06-07 |
| JP7111722B2 (ja) | 2022-08-02 |
| KR20190077340A (ko) | 2019-07-03 |
| CA3037883A1 (en) | 2018-03-29 |
| IL265521B1 (en) | 2024-05-01 |
| AU2017331260A1 (en) | 2019-05-16 |
| US11851441B2 (en) | 2023-12-26 |
| RU2019111768A (ru) | 2020-10-23 |
| IL265521A (en) | 2019-05-30 |
| MA46291A (fr) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3303396T3 (da) | Antistoffer mod ox40 og anvendelser deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3423087T3 (da) | Kombinationsterapi mod cancer | |
| DK3283527T3 (da) | Kombinationsterapi mod cancer | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
| DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3212670T3 (da) | Kombinationsterapi mod cancer | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK3256598T3 (da) | Svampestammer og anvendelsesfremgangsmåder | |
| DK3395801T3 (da) | Arylazolforbindelse og skadedyrsbekæmpelsesmiddel | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3606928T3 (da) | Makrocyklisk forbindelse og anvendelser deraf | |
| DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3253800T3 (da) | Prostata antigen standarder og bruge deraf | |
| DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3071563T3 (da) | Midler mod cancer og fremstilling deraf | |
| DK3448419T3 (da) | Interferon-beta-antistoffer og anvendelser deraf | |
| DK3417058T3 (da) | Sortase-modificerede molekyler og anvendelser deraf |